Stanford University
Showing 21-30 of 84 Results
-
Bita Fakhri, MD, MPH
Associate Professor of Medicine (Hematology)
BioDr. Bita Fakhri is an Associate Professor of Medicine in the Division of Hematology at Stanford University School of Medicine. She specializes in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), hairy cell leukemia, Richter’s syndrome, and other hematologic malignancies.
As a clinical scientist, Dr. Fakhri is dedicated to patient care, trainee education, and the development of novel therapies for individuals with CLL/SLL. She has co-authored numerous publications focusing on CLL, targeted therapies, and cellular therapies in hematologic malignancies.
Dr. Fakhri currently serves as Director of the CLL Clinical Trial Portfolio at Stanford. In addition, she is actively involved in building infrastructure to expand access to clinical trials and promote equity in care for underserved and marginalized populations across the Stanford catchment area. -
Jason Gotlib
Professor of Medicine (Hematology)
Current Research and Scholarly InterestsMy research interests include phase I/II clinical trial evaluation of novel therapies for the following diseases:
--Myelodysplastic syndromes (MDS)
--Chronic myelogenous leukemia (CML)
--Acute myelogenous leukemia (AML)
--Myeloproliferative disorders (MPDs) including:
Hypereosinophilic syndrome
Systemic mastocytosis
BCR-ABL-negative MPDs -
Peter Greenberg
Professor of Medicine (Hematology), Emeritus
Current Research and Scholarly InterestsDr Greenberg's clinical research involves design and coordination of clinical trials using experimental drugs with biologic focus for both lower and higher risk MDS patients not responding to standard therapies. These studies are particularly based on his prior laboratory investigations of gene expression and hematopoietic regulation in MDS patients. He is Coordinator of the International Working Group for Prognosis in MDS (IWG-PM) which generated the revised MDS classification system (the IPSS-R) and the mutation-based prognostic risk system, the IPSS-Molecular (IPSS-M). This project uses such findings to more specifically characterize and treat MDS patients. He is Chair of the NCCN Practice Guidelines Panel for MDS.
-
Ruwan Gunaratne
Instructor, Medicine - Hematology
BioRuwan Gunaratne, MD, PhD is an Instructor in Hematology at Stanford University School of Medicine and a board-certified hematologist-oncologist with a clinical focus on acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). His clinical and translational research centers on improving disease monitoring in myeloid cancers using personalized circulating tumor DNA (ctDNA) profiling, a blood-based approach designed to more sensitively track measurable residual disease (MRD), assess treatment response, refine risk stratification, and detect relapse earlier across the myeloid disease spectrum. Dr. Gunaratne’s work has been recognized with awards from the American Society of Hematology and the Stanford Cancer Institute, and he is actively committed to advancing precision medicine approaches for patients with myeloid malignancies.
